Full-Time

Manager - Program Management

Entrada Therapeutics

Entrada Therapeutics

201-500 employees

Develops intracellular therapeutics using endosomal escape

Compensation Overview

$127k - $159k/yr

Boston, MA, USA

Hybrid

Remote option exists but requires regular on-site presence at Boston, MA.

Category
Biology & Biotech (2)
,
Required Skills
Risk Management
Requirements
  • BA/BS degree required, with 8+ years in clinical and drug development within the biotech/pharmaceutical industry, with 3+ years in clinical-stage project/program management.
  • Strong understanding of drug development and how various functions integrate.
  • Proficiency in project management software (MS Project) and experience with timeline visualization software (e.g. OnePager).
  • Excellent organizational skills and attention to detail.
  • The ability to work effectively across functions.
  • Ability to manage multiple priorities in a fast-paced, dynamic environment.
  • Excellent verbal and written communication skills.
  • Desire to work in an innovative and collaborative environment.
Responsibilities
  • Provide program management support to multiple clinical development project/program teams.
  • Develop and maintain detailed end-to-end integrated program timelines; track and monitor key interdependencies and milestones.
  • Support development of program meeting agendas and outcomes; document and track actions and decisions.
  • Collaborate with cross-functional teams to ensure alignment with company and program objectives.
  • Identify and track program risks, issues, and dependencies; ensure communication and awareness across key stakeholders.
  • Apply PM best practices and methodologies to contribute to the growth and development of the Program Management Team.
Desired Qualifications
  • PMP preferred but not required.

Entrada Therapeutics focuses on developing a new class of medicines to treat devastating diseases by delivering therapies inside cells. Its core technology, the Endosomal Escape Vehicle (EEV) platform, helps drugs escape from endosomes—cellular compartments that often trap or degrade treatments—so they can reach intracellular targets. The product pipeline centers on EEV-therapeutics, including candidates for Duchenne muscular dystrophy and other neuromuscular diseases, with ENTR-601-45 currently cleared by UK and EU regulators to begin clinical trials. What sets Entrada apart is its explicit emphasis on enabling intracellular delivery to access targets that were previously hard to treat, using a platform-agnostic delivery approach that can work with a range of therapeutics such as oligonucleotides. The company’s goal is to advance multiple EEV-therapeutics through clinical development to address rare and other hard-to-treat diseases and reach patients who need new treatment options.

Company Size

201-500

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • ELEVATE-45-201 and Cohort 2 data by end-2026 could demonstrate dose-dependent dystrophin improvements.
  • Early functional benefit signal in Time to Rise velocity suggests clinical relevance beyond biomarkers.
  • $255M cash runway extends operations into Q3 2027, enabling multiple trial readouts.

What critics are saying

  • ENTR-601-44 Cohort 1 achieved only 2.36% dystrophin increase versus 10% investor expectations.
  • Sarepta's Elevidys dominates DMD market with $400M+ 2025 sales and proven efficacy.
  • Cash burn of $39.7M quarterly forces dilutive fundraising or R&D cuts within 18 months.

What makes Entrada Therapeutics unique

  • EEV platform enables intracellular delivery to previously undruggable targets across multiple organs.
  • Multi-exon DMD pipeline (44, 45, 50, 51) addresses broader patient population than competitors.
  • Vertex partnership validates EEV platform for myotonic dystrophy type 1 co-development.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Entrada Therapeutics who can refer or advise you

Benefits

401(k) Company Match

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

1%
The Manila Times
Feb 4th, 2026
Entrada Therapeutics to Present at Upcoming Investor Conferences

Entrada Therapeutics to present at upcoming investor conferences. By GlobeNewswire February 4, 2026 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m. Eastern Time in New York, NY. TD Cowen 46th Annual Health Care Conference Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 3, 2026, at 2:30 p.m. Eastern Time in Boston, MA. Live webcasts will be available on the Investor Relations section of the Company's website at www.entradatx.com. Replays will be available on the Entrada website for 90 days following the events. About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV(TM)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular, ocular and other diseases, leveraging next-generation EEVs, novel oligonucleotide sequences and an advanced protein engineering platform. The Company's lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Investor Contact Karla MacDonald Chief Corporate Affairs Officer Media Contact Megan Prock McGrath CTD Comms, LLC

Stock Titan
Sep 2nd, 2025
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

DMDHelp
Aug 7th, 2025
Entrada Therapeutics doses first participant in Exon 44 skipping program; provides updates to other exon-skipping programs

Entrada Therapeutics, which received early funding from CureDuchenne, has provided updates on the status of several exon skipping programs.

The Manila Times
Feb 27th, 2025
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Entrada Therapeutics reports Fourth Quarter and Full Year 2024 Financial Results.

MarketBeat
Nov 28th, 2024
Massachusetts Financial Services Co. MA Invests $1.11 Million in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

MA invests $1.11 million in Entrada Therapeutics, Inc. (NASDAQ:TRDA).